Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pradigastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 known ✓ | O75907 | 12/20 | 0.84 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pradigastat SCHEMBL29516945 | 1.00 | DGAT1 (0.84) | DGAT1PSEN1PSEN2APH1BNCSTN | |
| Pradigastat SCHEMBL180536 | 0.91 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL16104874 | 0.91 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL1289309 | 0.91 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL29358725 | 0.91 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL15131446 | 0.90 | DGAT1 (0.84) | DGAT1USP30 | |
| SCHEMBL180703 | 0.89 | DGAT1 (0.81) | DGAT1USP30 | |
| Acetic Acid SCHEMBL15531774 | 0.84 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL27737366 | 0.84 | DGAT1 (0.73) | DGAT1USP30 | |
| SCHEMBL29068729 | 0.84 | DGAT1 (0.76) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874775-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119841865-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119823184-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119343343-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119072474-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-115698003-B | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| CN-110382503-B | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |